255 related articles for article (PubMed ID: 25510351)
21. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
22. Expression of androgen receptors in triple negative breast carcinomas.
Mrklić I; Pogorelić Z; Capkun V; Tomić S
Acta Histochem; 2013 May; 115(4):344-8. PubMed ID: 23031358
[TBL] [Abstract][Full Text] [Related]
23. Triple-negative breast cancer: molecular subtypes and targeted therapy.
Hirshfield KM; Ganesan S
Curr Opin Obstet Gynecol; 2014 Feb; 26(1):34-40. PubMed ID: 24346128
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.
Gasparini P; Fassan M; Cascione L; Guler G; Balci S; Irkkan C; Paisie C; Lovat F; Morrison C; Zhang J; Scarpa A; Croce CM; Shapiro CL; Huebner K
PLoS One; 2014; 9(2):e88525. PubMed ID: 24505496
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor status is highly conserved during tumor progression of breast cancer.
Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor status in female breast cancer: RT-PCR and Western blot studies.
Bryś M; Wójcik M; Romanowicz-Makowska H; Krajewska WM
J Cancer Res Clin Oncol; 2002 Feb; 128(2):85-90. PubMed ID: 11862478
[TBL] [Abstract][Full Text] [Related]
27. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
[TBL] [Abstract][Full Text] [Related]
28. L1CAM in human cancer.
Altevogt P; Doberstein K; Fogel M
Int J Cancer; 2016 Apr; 138(7):1565-76. PubMed ID: 26111503
[TBL] [Abstract][Full Text] [Related]
29. Active allele loss of the androgen receptor gene contributes to loss of androgen receptor expression in female breast cancers.
Shan L; Yang Q; Nakamura M; Nakamura Y; Mori I; Sakurai T; Kakudo K
Biochem Biophys Res Commun; 2000 Aug; 275(2):488-92. PubMed ID: 10964692
[TBL] [Abstract][Full Text] [Related]
30. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
[TBL] [Abstract][Full Text] [Related]
31. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
33. DNA hypomethylation at the CpG island is involved in aberrant expression of the L1 cell adhesion molecule gene in colorectal cancer.
Kato K; Maesawa C; Itabashi T; Fujisawa K; Otsuka K; Kanno S; Tada H; Tatemichi Y; Kotani K; Oikawa H; Sugai T; Wakabayashi G; Masuda T
Int J Oncol; 2009 Sep; 35(3):467-76. PubMed ID: 19639167
[TBL] [Abstract][Full Text] [Related]
34. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
35. Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer.
Cheng CL; Thike AA; Tan SY; Chua PJ; Bay BH; Tan PH
Breast Cancer Res Treat; 2015 May; 151(1):99-111. PubMed ID: 25868865
[TBL] [Abstract][Full Text] [Related]
36. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484
[TBL] [Abstract][Full Text] [Related]
37. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers.
Corrado G; Laquintana V; Loria R; Carosi M; de Salvo L; Sperduti I; Zampa A; Cicchillitti L; Piaggio G; Cutillo G; Falcioni R; Vizza E
J Exp Clin Cancer Res; 2018 Jul; 37(1):139. PubMed ID: 29980240
[TBL] [Abstract][Full Text] [Related]
38. FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma.
Perez-Balaguer A; Ortiz-Martínez F; García-Martínez A; Pomares-Navarro C; Lerma E; Peiró G
Breast Cancer Res Treat; 2015 Sep; 153(2):465-74. PubMed ID: 26298189
[TBL] [Abstract][Full Text] [Related]
39. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
Moore NL; Buchanan G; Harris JM; Selth LA; Bianco-Miotto T; Hanson AR; Birrell SN; Butler LM; Hickey TE; Tilley WD
Endocr Relat Cancer; 2012 Aug; 19(4):599-613. PubMed ID: 22719059
[TBL] [Abstract][Full Text] [Related]
40. Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer.
Goto Y; Thike AA; Ong CCH; Lim JX; Md Nasir ND; Li H; Koh VCY; Chen XY; Yeong JPS; Sasano H; Tan PH
J Clin Pathol; 2020 Mar; 73(3):147-153. PubMed ID: 31563883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
